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B cell activating factor (BAFF; Schneider et al., 
1999), which is also called BLyS (Moore et al., 
1999), THANK (Mukhopadhyay et al., 1999), 
TALL-1 (Shu et al., 1999), or zTNF4 (Gross et al.,   
2000), is a TNF family member (TNFSF13B 
[A000383]) critical for maintenance of normal   
B cell development and homeostasis (Thompson   
et al., 2000; Schiemann et al., 2001; Schneider 
et al., 2001). Three receptors, B cell matura-
tion antigen (BCMA; TNFRSF17 [A000374]; 
Madry et al., 1998), transmembrane activator 
and calcium modulator and cyclophilin ligand 
interactor (TACI; TNFRSF13B [A002248]; 
von Bülow et al., 2000), and BAFF receptor 
(BAFF-R; Thompson et al., 2001; also called 
BR3 or TNFRSF13C [A002648]) have been 
identified as receptors for BAFF. BCMA and 
BAFF-R are predominantly expressed  on  B 
lymphocytes, whereas TACI can be found on 
B cells and activated T cells (von Bülow and 
Bram, 1997). Initial studies of the effects of 
BAFF on B cell physiology demonstrate that it 
co-stimulates B cell proliferation and immuno-
globulin secretion (Moore et al., 1999; Schneider 
et al., 1999). Transgenic overexpression of BAFF 
in mice results in elevated Bcl-2 levels and pro-
longed survival of B cells, manifesting in in-
creased numbers of mature B cells in the spleen 
and periphery and development of autoimmune-
like characteristics reminiscent of systemic lupus 
erythematosus (Mackay et al., 1999; Gross et al., 
2000;  Khare  et  al.,  2000).  Peripheral  B  cell 
maturation is arrested in BAFF-deficient mice, 
resulting in almost complete loss of follicular 
and marginal zone B lymphocytes (Schiemann   
et al., 2001).
The underlying mechanism responsible for 
the effect of BAFF on B cells remains poorly 
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The cytokine B cell activating factor (BAFF) and its receptor, BAFF receptor (BAFF-R), 
modulate signaling cascades critical for B cell development and survival. We identified a 
novel mutation in TNFRSF13C, the gene encoding human BAFF-R, that is present in both 
tumor and germline tissue from a subset of patients with non-Hodgkin lymphoma. This 
mutation encodes a His159Tyr substitution in the cytoplasmic tail of BAFF-R adjacent  
to the TRAF3 binding motif. Signaling through this mutant BAFF-R results in increased  
NF-B1 and NF-B2 activity and increased immunoglobulin production compared with the 
wild-type (WT) BAFF-R. This correlates with increased TRAF2, TRAF3, and TRAF6 recruit-
ment to His159Tyr BAFF-R. In addition, we document a requirement for TRAF6 in WT 
BAFF-R signaling. Together, these data identify a novel lymphoma-associated mutation in 
human BAFF-R that results in NF-B activation and reveals TRAF6 as a necessary compo-
nent of normal BAFF-R signaling.
© 2010 Hildebrand et al.  This article is distributed under the terms of an At-
tribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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an association between the development of human disease with 
genetic variation in genes encoding BAFF and its receptors. 
Mutations in TNFRSF13B (TACI) were identified in patients 
with familial common variable immunodeficiency (CVID) 
and IgA deficiency (Castigli et al., 2005; Salzer et al., 2005), 
and we have found that single nucleotide polymorphisms 
(SNPs) in TNFSF13B (BAFF) are associated with elevated 
BAFF levels and risk for developing NHL (Novak et al., 
2006, 2009). To build upon these findings, we sequenced 
the TNFSF13B, TNFSF13, TNFRSF13B, TNFRSF17, and 
TNFRSF13C genes in NHL patients to identify novel genetic 
variants that may be associated with NHL risk. This approach 
identified a mutation in TNFRSF13C that results in a histi-
dine 159–to–tyrosine substitution located in the cytoplasmic 
tail of BAFF-R. Analysis of cells expressing H159Y BAFF-R 
demonstrates that this mutation results in increased BAFF-R–
mediated NF-B1 and NF-B2 activation. The enhanced signal 
activated by BAFF-R H159Y is coupled with a severalfold in-
crease in TRAF3, TRAF2, and TRAF6 recruitment to BAFF-R.   
We demonstrate that recruitment of TRAF6 to BAFF-R is not 
unique to the mutant H159Y BAFF-R but is also an important 
and necessary feature of normal BAFF-R signaling.
RESULTS
Identification of the BAFF-R His159Tyr mutation
We sequenced the TNFSF13B, TNFSF13, TNFRSF13B, 
TNFRSF17, and TNFRSF13C genes to identify additional 
understood, in part because of the complexity introduced by 
multiple BAFF-binding receptors. However, a central role for 
BAFF-R in BAFF biology has been suggested by studies dem-
onstrating that A/WySnJ mice, which carry a mutation in 
BAFF-R, and BAFF-R deficient mice, show a loss of mature 
peripheral B cells, a phenotype similar to BAFF-deficient mice 
(Gross et al., 2001; Thompson et al., 2001; Yan et al., 2001). 
Current models suggest that BAFF binding to BAFF-R results 
in a coordinated assembly of a regulatory complex consisting of 
cIAP1, cIAP2, TRAF2, TRAF3, and NIK. Formation of this 
complex results in ubiquitin-mediated proteasomal degradation 
of TRAF3 followed by NIK stabilization and NF-B2 activa-
tion (Vallabhapurapu et al., 2008; Zarnegar et al., 2008). In ad-
dition to NF-B2 activation, BAFF-R has been shown to 
be essential for BAFF-mediated phosphorylation of AKT and 
Erk1/2 through IKK1 (Otipoby et al., 2008). However, the 
proximal events that mediate activation of this signaling cascade 
are not fully characterized.
The requirement for BAFF and BAFF-R in normal human 
and mouse B cells is well studied, but there is also significant 
evidence to suggest that BAFF plays an important role in ma-
lignant B cell proliferation and survival (Briones et al., 2002; 
He et al., 2004; Novak et al., 2004; Fu et al., 2006). Serum 
BAFF levels are elevated in patients with non-Hodgkin lym-
phoma (NHL), and high BAFF levels correlate with aggres-
sive disease and a poor response to therapy (Novak et al., 
2004). There is also increasing genetic evidence, suggesting 
Figure 1.  Identification of the BAFF-R His159Tyr SNP. (A) TNFRSR13C was sequenced on both sense (bottom chromatogram) and antisense (top 
chromatogram) strands, and a heterozygous cytosine-to-thymidine transition at position 519 (C519T) was identified. (B) A multiple sequence alignment 
of a sample of mammalian BAFF-R amino acid sequences, showing evolutionary conservation of the cytoplasmic portion and the location of the missense 
substitution of tyrosine (Y) for histidine (H) in codon 159. Symbols below the sequence alignment indicate when residues across species encode for iden-
tical (*), conserved (:), or semiconserved (.) amino acids.JEM VOL. 207, November 22, 2010 
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increased p100 processing at baseline and upon BAFF stimula-
tion in BAFF-RHis159-Tyr–expressing cells. Increased NF-B2 
signaling  was  also  evident  at  lower  ligand  concentrations.   
Using 50 ng/ml BAFF (Fig. 2 A, bottom), we saw significant 
increases in p100 processing (P = 0.0009 and P = 0.0008 at the 
0- and 3-h time points, respectively; n = 3). p100 processing 
was not detected in the vector control cells and minimal p100 
processing was detected in cells expressing the TRAF3 binding–
deficient BAFF-RAVAAA. Data from three independent experi-
ments are shown graphically in Fig. 2 A (right). In parallel 
experiments, we tested the ability of BAFF-RWT and BAFF-
RHis159-Tyr to activate transcription of a NF-B reporter gene 
plasmid (Fig. 2 B). Consistent with the p100 processing re-
sults, BAFF-RHis159-Tyr induced increased NF-B activation 
compared with BAFF-RWT (P = 0.01; n = 3). These results 
are not a result of variation in BAFF-R expression between 
the cell lines (Fig. S1, B and C).
Because signaling by TNFR family members can show 
cell type–specific features (Bishop, 2004), it was important to 
determine whether BAFF-RHis159-Tyr could induce increased 
NF-B activation in physiologically relevant B lineage cells. 
Mature B cells can express both BAFF-R and TACI, making 
it difficult to ascribe BAFF-induced signaling events in B cells 
to BAFF-R alone. We therefore used a chimeric receptor 
approach and generated A20.2J mouse B cell lines that ex-
press a receptor that consists of the extracellular domain of 
human CD40 fused with the transmembrane and cytoplasmic 
domain of mouse BAFF-R (hCD40–mBAFF-R; Fig. S1 D). 
This approach allows us to specifically study BAFF-R re-
sponses in B lineage cells in the absence of TACI signaling 
using hCD154 (the natural ligand for hCD40) or an agonistic 
anti-hCD40 antibody (G28.5). This chimera was previously 
demonstrated to activate NF-B2 and TRAF3 degradation 
(Morrison et al., 2005) and can therefore serve as a valid 
model to study BAFF-R signals. A20.2J B cells were stably 
transfected to express hCD40–BAFF-RWT or hCD40–BAFF-
RHis159-Tyr, and clones with matched surface expression of 
chimeric receptor (Fig. S1 E) were incubated with Hi5 insect 
cells expressing hCD154 (Rowland et al., 2007). Early phos-
phorylation of IB was significantly enhanced (P = 0.05 
and P = 0.018 at 2 and 5 min, respectively; n = 3) after stimu-
lation  of  hCD40–BAFF-RHis159-Tyr  (Fig.  2  C).  Likewise, 
hCD40–BAFF-RHis159-Tyr  induced  a  significant  increase  in 
basal levels of p52 and RelB nuclear localization (P = 0.009 
and 0.02, respectively; n = 4) and in nuclear RelB levels at   
novel genetic variants that may be associated with NHL. 
Among 40 individual samples (20 controls and 20 follicular 
lymphoma [FL] cases) that were bidirectionally sequenced, 
we identified a heterozygous cytosine-to-thymidine transition 
in one patient specimen at position 519 (C519T, rs61756766, 
National Center for Biotechnology Information [NCBI]   
reference sequence NM_052945.3) of TNFRSF13C (Fig. 1 A). 
The C519T transition predicts a missense substitution of 
tyrosine for histidine in codon 159 (H159Y) in the highly 
conserved cytoplasmic tail of BAFF-R, adjacent to the TRAF3 
binding motif PVPAT (Fig. 1 B). This genetic variation was 
previously identified in 1/48 patients studied with CVID; 
however, it was not found to be associated with immuno-
deficiency disease or a change in BAFF-R mRNA or protein 
expression (Losi et al., 2005). We next expanded our analysis 
of BAFF-R H159Y and analyzed NHL tumor biopsies for 
the presence of the mutation (Table I). 4/41 FLs, 2/42 dif-
fuse large B cell lymphomas (DLBCLs), 1/22 lymphoplasma-
cytic  lymphomas,  and  1/24  mucosal-associated  lymphoid 
tissue lymphomas (MALTs) carried the heterozygous muta-
tion. When feasible, we examined matched tumor and germ-
line tissue from patients and found that the BAFF-R mutation 
was present in both germline and tumor tissue in 2/2 FLs and 
2/2 DLBCLs tested. The BAFF-R H159Y mutation was not 
detected in any of the normal control tissues (n = 100). These 
data  identify  a  novel  lymphoma-associated  mutation  in 
BAFF-R, and the presence of the mutation in germline tissue 
suggests that the BAFF-R mutation may be associated with 
lymphoma risk.
Increased NF-B activation by BAFF-R His159Tyr
Given its close proximity to the TRAF3 binding site in the 
cytoplasmic domain of BAFF-R, we first wanted to deter-
mine if the H159Y mutation altered BAFF-induced signal-
ing. We generated HEK293 cells that express HA-tagged 
WT BAFF-R (WT), BAFF-R with the H159Y mutation 
(H159Y), or BAFF-R with an ablated TRAF3 binding site as 
a negative control (AVAAA; Fig. S1 A; Morrison et al., 2005). 
Expression of BAFF-R protein was confirmed by Western 
blot analysis and flow cytometry (Fig. S1 B and C).
Using these cell lines, we examined the ability of BAFF-
RWT and BAFF-RHis159-Tyr to activate processing of p100 NF-
B2 to the active p52 subunit. Stimulation of both BAFF-RWT 
and BAFF-RHis159-Tyr with 200 ng/ml BAFF for 3 or 6 h re-
sulted in p100 processing (Fig. 2 A, top). We observed   
Table I.  Identification of the BAFF-R H159Y mutation in biopsy specimens from patients with NHL
NHL subtype Number screened Number positive for BAFF-R H159Y Percent positive for BAFF-R H159Y
%
DLBCL n = 42 n = 2 4.8
FL n = 41 n = 4 10
Lymphoplasmacytic lymphoma n = 22 n = 1 4.5
MALT n = 24 n = 1 4.1
NHL subtype was determined by a board-certified Mayo Clinic Hematopathologist.2572 BAFF-R mutation in non-Hodgkin lymphoma | Hildebrand et al.
(Fig. S2), stimulated the cells with anti-hCD40 to activate the 
chimeric receptor, and measured IgM secretion (Fig. 3). As a 
control, cells were also stimulated with an isotype control anti-
body or anti-mCD40, which activates the endogenous full-
length mCD40 expressed by these cells. Upon stimulation, 
cells expressing hCD40–BAFF-RHis159-Tyr produced fourfold 
more  IgM  compared  with  hCD40–BAFF-RWT–expressing 
cells (n = 3, P = 0.0401), which is consistent with the increase 
in IB phosphorylation observed earlier. Both types of sub-
clones exhibited equal IgM secretion when stimulated via en-
dogenous mouse CD40. These data show that the BAFF-R 
His159Tyr mutation has biological impact on B cell function.
Increased TRAF recruitment by BAFF-R His159Tyr
To define the mechanism by which BAFF-RHis159-Tyr acti-
vates  increased  NF-B  pathway  activation,  we  examined 
BAFF-R signaling events upstream of NF-B activation. One 
of the most proximal signaling events to occur upon BAFF 
stimulation is the recruitment of TRAF3 to the BAFF-R   
cytoplasmic tail. TRAF2 and TRAF6 have also been re-
ported  to  associate  with  TACI  (Xia  et  al.,  2000)  and 
BCMA (Hatzoglou et al., 2000), so we also analyzed their 
ability to associate with BAFF-R. Using A20.2J B cells express-
ing  hCD40–BAFF-RWT  and  hCD40–BAFF-RHis159-Tyr, 
3 and 6 h after stimulation (P = 0.02 and 0.005; n = 4; Fig. 2 D), 
confirming the increase in NF-B activation induced by 
BAFF-RHis159-Tyr in HEK293 cells. Collectively, these data 
demonstrate that stimulation of BAFF-RHis159-Tyr, either as 
full-length or chimeric receptor, results in significantly in-
creased NF-B activity compared with BAFF-RWT.
BAFF-R His159Tyr drives increased immunoglobulin production
The results in the previous section clearly indicate that the 
His159Tyr mutation alters signaling by BAFF-R. We next 
addressed if this alteration in early signals has biological im-
pact on B cell function. BAFF-R plays an important role in 
early B cell maturation from transitional to mature stages 
(Schneider et al., 2001), but we could not test this function as 
we do not currently have access to B cells from individuals 
bearing this mutation. However, BAFF also plays a central 
role  in  regulation  of  immunoglobulin  secretion  by  B  cells 
(Moore et al., 1999; Schneider et al., 2001). To determine 
whether BAFF-RHis159-Tyr affected antibody production, we 
used a CH12.LX mature B cell line that has been previously 
shown to secrete phosphatidyl choline–specific IgM in re-
sponse to CD40 stimulation in a NF-B–dependent manner 
(Hsing and Bishop, 1999). We stably transfected CH12.LX 
cells with hCD40–BAFF-RWT or hCD40–BAFF-RHis159-Tyr 
Figure 2.  BAFF-R His159Tyr exhibits 
enhanced signaling ability. (A) HEK-293 
cells expressing BAFF-RWT, BAFF-RH159Y, BAFF-
RAVAAA, or a vector control were stimulated 
with 200 or 50 ng/ml BAFF for 0, 3, or 6 h.  
NF-B2 p100 processing to p52 was analyzed by 
immunoblotting. Levels of p52 and actin were 
quantified by densitometry, and combined 
analysis of three independent experiments is 
shown in the bar graph. (B) NF-B luciferase 
reporter assay in HEK-293 cells expressing 
BAFF-RWT, BAFF-RH159Y, or BAFF-RAVAAA.  
(C) A20.2J B cells expressing hCD40–BAFF-RWT 
or hCD40–BAFF-RH159Y chimeras were incubated 
with media alone (M), uninfected Hi5 cells (0), 
or Hi5-hCD154 cells for the indicated times. 
Levels of phospho-IB, total IB, and actin 
were examined by Western blotting and quan-
tified by densitometry. Combined analysis of 
four independent experiments is shown in  
the bar graph. (D) CH12.LX B cells expressing 
hCD40–BAFF-RWT, hCD40–BAFF-RH159Y, or 
hCD40–BAFF-RAVAAA were incubated with 
anti–human CD40 (G28.5) or isotype control 
(0). Levels of p52, RelB, and YY1 in the nuclear 
cell fraction were examined by Western  
blotting and quantified by densitometry.  
Combined analysis of four independent ex-
periments is shown in the bar graph. In all 
analyses, error bars represent the ± SEM and 
statistical comparisons were made between 
BAFF-RWT and BAFF-RH159Y. *, P < 0.05.JEM VOL. 207, November 22, 2010 
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we analyzed the ability of each receptor to recruit TRAF2, 
TRAF3, and TRAF6 after stimulation (15 or 60 min) and 
immunoprecipitation with the anti-hCD40 antibody G28.5 
(Fig.  4  A).  Compared  with  BAFF-RWT,  BAFF-RHis159-Tyr 
conferred a fivefold increase in recruitment of TRAF2 (P = 
0.001), a fourfold increase in TRAF3 (P = 0.058), and a 25-
fold increase in TRAF6 (P = 0.043; 60-min time point, n = 4; 
Fig. 4 B). The increased TRAF association was not a result of 
differences in BAFF-R or TRAF expression by each cell line 
(Fig. S1 E and Fig. S3, respectively). Data from four indepen-
dent experiments are shown graphically in Fig. 4 B. To verify 
that the increase in TRAF association was not an artifact 
of using a chimeric form of BAFF-RHis159-Tyr, we performed 
immunoprecipitations of full-length BAFF-RWT or BAFF-
RHis159-Tyr expressed in HEK293 cells after stimulation with 
BAFF. Consistent with our observations using hCD40–
BAFF-R in B cells, there was an increase in TRAF2 and 6 asso-
ciations with BAFF-RHis159-Tyr versus BAFF-RWT (Fig. 4 C). 
The  increased  association  was  not  a  result  of  increased   
BAFF-R or TRAF expression (Fig. 4 C, bottom, lysate). 
These results suggest that the increased NF-B activity in-
duced by BAFF-RHis159-Tyr may be, in part, a result of in-
creased TRAF recruitment. Additionally, these results also 
reveal for the first time that TRAF6 can associate with BAFF-R 
and thus potentially participate in BAFF-R signaling.
TRAF6 associates with BAFF-R and is required  
for BAFF-R signaling
TRAF6 has not previously been shown to interact with 
BAFF-R or play a role in BAFF-R–mediated signaling. The 
studies in the previous section clearly demonstrate that TRAF6 
is recruited to BAFF-R; however, both of these models used 
exogenous expression of BAFF-R. To determine if TRAF6 
is recruited to endogenous full-length BAFF-R, unmodified 
mouse A20.2J B cells (WT) were treated with recombinant 
BAFF, and endogenous BAFF-R was immunoprecipitated 
and analyzed for TRAF recruitment (Fig. 5 A, left). TRAF6 
Figure 3.  BAFF-R His159Tyr stimulates enhanced immunoglobulin 
production. CH12.LX cells stably expressing hCD40–BAFF-RWT or hCD40–
BAFF-RH159Y were stimulated for 72 h with 2 µg/ml of agonistic mCD40-
specific antibody, hCD40-specific antibody, or isotype control. Numbers of 
IgM-secreting B cells (±SEM) from three independent experiments are 
shown. *, P < 0.05. Pfc, plaque forming cell.
Figure 4.  The His159Tyr BAFF-R mutant recruits increased amounts 
of TRAF2, 3, and 6. (A) A20.2J B cells expressing hCD40–BAFF-RWT or 
hCD40–BAFF-RHis159Tyr chimeras were subjected to combined stimulation 
and immunoprecipitation with the hCD40-specific antibody G28.5. (iso 15, 
15 min with isotype control). The immunoprecipitate was probed for the 
presence of TRAF2, TRAF3, TRAF6, and hCD40–BAFF-R. (B) Levels of co-
immunoprecipitated TRAF2, 3, and 6 were normalized to the amount of 
hCD40–BAFF-R immunoprecipitated. Histogram represents the mean ± SEM 
of four independent experiments. *, P < 0.05 (BAFF-RH159Y vs. BAFF-RWT).  
(C) HEK-293 cells expressing HA-tagged BAFF-RWT, BAFF-RH159Y, BAFF-RAVAAA, 
or a vector control were stimulated with BAFF and subjected to immunopre-
cipitation using an HA-specific antibody. Associated protein or total lysates 
were probed for the presence of TRAF2 or TRAF6 by Western blotting.
was coimmunoprecipitated with BAFF-R within 10 min of 
BAFF stimulation. We also examined TRAF2 and TRAF3 
recruitment to BAFF-R. Similar to results seen in Fig. 4,   2574 BAFF-R mutation in non-Hodgkin lymphoma | Hildebrand et al.
of TRAF6, TRAF2 and TRAF3 were 
recruited normally to BAFF-R, indicat-
ing that TRAF6 is not required for as-
sociation of TRAF2 and TRAF3 with 
BAFF-R. Lack of TRAF6 expression 
and equivalent BAFF-R expression by 
WT and TRAF6 KO cells was con-
firmed  by  Western  blot  analysis  and 
flow cytometry (Fig. S4, A and B). The 
association  of  TRAF6  with  BAFF-R 
was  also  evident  in  primary  mouse 
splenic B cells (Fig. 5 B) and in the human Karpas B cell line 
(Fig. 5 C), indicating that this novel interaction is not re-
stricted to a specific cell line or species. The recruitment of 
TRAF6 to hBAFF-R in the absence of exogenous BAFF is 
attributed to endogenous BAFF production by the Karpas   
we detected recruitment of both TRAFs to endogenous 
BAFF-R. The requirement of TRAF6 for TRAF2 and TRAF3 
recruitment to BAFF-R has not been explored and we therefore 
performed the same experiment in TRAF6-deficient A20.2J 
B cells (TRAF6 KO; Rowland et al., 2007). In the absence 
Figure 5.  TRAF6 is recruited to BAFF-R  
in B cells and is required for BAFF- and 
BAFF-R–induced prosurvival signals.  
(A–C) Mouse A20.2J and A20.2J TRAF6 KO cells  
(A), primary mouse T cell–depleted splenocytes 
(B), or human Karpas B cells (C) were stimu-
lated with BAFF, and the Brij58 insoluble (lipid 
raft enriched) fraction (lysate) was subjected to 
immunoprecipitation with a mouse or human 
BAFF-R–specific antibody or isotype control 
(iso). Immunoprecipitated sample was probed 
for the presence of TRAF6, 2, or 3. A and C are 
representative of three independent experi-
ments and B is representative of two indepen-
dent experiments. (D) A20.2J WT, A20.2J TRAF6 
KO, and A20.2J TRAF6 KO cells expressing full-
length TRAF6 were incubated with BAFF for the 
indicated times. (E) A20.2J WT and A20.2J 
TRAF6 KO cells expressing the hCD40-BAFFR 
chimera were incubated with hCD154 for the 
indicated times. Western blots were performed 
to detect phosphorylated IB, total IB, and 
actin. D and E are representative of three inde-
pendent experiments with similar results.  
(F) A20.2J WT and A20.2J TRAF6 KO cells ex-
pressing the hCD40-BAFFR chimera were incu-
bated with agonistic mCD95/Fas-specific 
antibody to induce apoptosis. Agonistic 
hCD40-specific antibody was used to activate 
the hCD40–BAFF-R chimera. Agonistic mouse 
CD40-specific antibody rescues in a TRAF6-
dependent manner and was used as a control 
(Benson et al., 2006). Isotype controls for each 
of these antibodies are named isotype 1, 2, and 
3, respectively. Subdiploid (apoptotic) cells were 
measured by flow cytometric analysis after 
propidium iodide staining. Data are plotted as 
the mean ± SEM of five independent experi-
ments, with the mean percentage of rescue 
calculated as described in Materials and meth-
ods. *, P < 0.05 (percentage of rescue in WT vs. 
TRAF6 KO cells).JEM VOL. 207, November 22, 2010 
Article
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those in CD79b to chronically activate signaling through the 
B cell receptor, suggests that dysregulation of signaling path-
ways contribute to NHL development. In accordance with 
this data, we have identified a novel lymphoma-associated 
mutation in BAFF-R that results in increased basal and BAFF-
induced NF-B activation. Our studies suggest that the muta-
tion is not specific to one subtype of NHL, although incidence 
was highest in FL (10%). Unlike DLBCL or MALT lym-
phoma, FL has not been shown to have constitutive NF-B 
activation. However, FL is a heterogeneous disease and gene 
set enrichment analysis suggests that t(14;18) negative FLs are 
enriched for NF-B and ABC-like gene signatures (Leich 
et al., 2009). Although this study focuses on the ability of 
BAFF-RHis159-Tyr to activate NF-B, we have preliminary 
data suggesting that BAFF-RHis159-Tyr also activates additional 
BAFF-R–mediated pathways, including Akt, which is acti-
vated in both FL (Gulmann et al., 2005) and DLBCL (Gupta 
et al., 2009). Therefore, the specific mechanism of how 
BAFF-RHis159-Tyr regulates tumor cell growth and develop-
ment may be through activation of multiple signaling cas-
cades. An expanded analysis of the presence of the mutation 
across the spectrum of all B cell malignancies and correlations 
with other clinical and biological parameters is currently on-
going and will hopefully lend insight into the function of the 
BAFF-RHis159-Tyr mutation.
In our initial analysis, we identified the BAFF-RHis159-Tyr 
mutation in NHL tissue, suggesting that it was a somatic mu-
tation acquired during tumor formation. However, further 
analysis on available matched patient tumor and germline 
DNA revealed that it was a germline mutation in four of four 
cases. Overall, in our sample, frequency of the BAFF-RHis159-Tyr 
mutation was 6.2% in NHL tumor DNA compared with   
0% in our 100 normal controls and 1.4% reported in the 
NCBI SNP database. Collectively, the increased frequency 
of the BAFF-RHis159-Tyr mutation in NHL compared with 
normal controls suggests that it may be a rare variant that 
confers risk to development of B cell lymphomas. In all cases 
analyzed, the mutation in BAFF-R was found to be hetero-
zygous. The absence of a homozygous mutation in BAFF-R 
does not exclude it from having functional consequence as 
gain-in-function,  haploinsufficiency,  or  dominant-negative 
effects are possible disease-causing mechanisms in heterozygous 
carriers. An example of this has been seen for TNFRSF13B 
(TACI), where C104R heterozygosity increases the risk for 
common variable immunodeficiency disorders and influences 
clinical presentation (Salzer et al., 2009). The ability of BAFF-
RHis159-Tyr to activate increased levels of NF-B suggests that 
it models an oncogenic gain-in-function mutation. Although 
these types of mutations have not been clearly identified in 
NHL, heterozygous germline gain-in-function mutations in 
KIT and PDFGRA have been shown to be associated with 
development of gastrointestinal stromal tumors (Beghini et al., 
2001; Chompret et al., 2004).
Constitutive  activation  of  NF-B  is  a  hallmark  of   
NHL (Vallabhapurapu and Karin, 2009), and the ability of 
BAFF-RHis159-Tyr to activate this signaling cascade could be 
B cell line, a common feature of Epstein-Barr virus–positive 
B cell lymphomas (He et al., 2003).
We next investigated whether TRAF6 is required for   
BAFF-mediated activation of NF-B. WT and TRAF6 KO 
A20.2J B cells were incubated with recombinant BAFF and phos-
phorylation and degradation of IB was analyzed (Fig. 5 D). 
BAFF stimulation of WT cells resulted in phosphorylation of 
IB, followed by degradation. In the absence of TRAF6, cells 
were unresponsive to BAFF and little IB phosphorylation 
was detected. To ensure the specificity for TRAF6, TRAF6 
KO cells were reconstituted with full-length TRAF6 (TRAF6 
KO + TRAF6) and analyzed for their ability to respond to 
BAFF (Fig. 5 D, right; and Fig. S4 A). Similar to WT cells, 
TRAF6 reconstituted cells were able to phosphorylate and de-
grade IB upon BAFF stimulation.
Because BAFF can bind both BAFF-R and TACI in the 
A20.2J B cells, we used the hCD40–BAFF-R chimera to con-
firm that BAFF-R specifically could induce TRAF6-dependent 
IB phosphorylation in B cells. WT and TRAF6-deficient 
A20.2J cells were stably transfected with hCD40–BAFF-RWT 
(Fig. S4 C) and incubated with hCD154. IB phosphoryla-
tion was observed at 2 and 5 min, as is the case with a BAFF-
induced signal, and phosphorylation was significantly reduced 
in TRAF6-deficient cells (Fig. 5 E). We did not detect any re-
producible difference in BAFF-R–mediated NF-B2 activa-
tion in these cell lines (unpublished data), which is consistent 
with observations made using BAFF stimulation of TRAF6-
deficient primary mouse B cells (Kobayashi et al., 2009).
To demonstrate a functional consequence of this defective 
IB phosphorylation, the previous observation that BAFF can 
rescue B cells from Fas/CD95-induced apoptosis (Hancz et al., 
2008) was examined in TRAF6-deficient A20.2J B cells express-
ing equal amounts of hCD40–BAFF-R and CD95 (Fig. S1 E 
and Fig. S4 B, respectively). Incubation of A20.2J cells with   
agonistic anti-CD95 antibody induces apoptotic cell death in 
70% of cells after 8 h as measured by staining with propid-
ium iodide. Concurrent incubation of cells with agonistic anti-
bodies that activate both CD95 and hCD40–BAFF-R inhibits 
CD95-mediated apoptotic cell death in 50% of A20.2J B cells 
(Fig. 5 F). This BAFF-R–mediated rescue from apoptosis is re-
duced over twofold (P = 0.0019, n = 5) in the absence of 
TRAF6. Together, these data reveal TRAF6 as a newly identi-
fied  member  of  the  BAFF-R–proximal  signaling  complex, 
with important roles in BAFF-R–induced IB activation and 
BAFF-R–mediated rescue from Fas-induced apoptosis.
DISCUSSION
Some of the genetic changes that lead to malignant transfor-
mation of B cells have been discovered, but many of the 
other contributing mechanistic details underlying transfor-
mation events are not yet known. Recent publications high-
light the role for gene mutations in the pathogenesis of NHL. 
Specifically, mutations in CARD11 (Lenz et al., 2008) and 
CD79B (Davis et al., 2010) are present in tumor biopsies 
from patients with activated B cell (ABC)–like DLBCL. The 
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also be required for the ubiquitination of TRAF6. It is not clear 
at this time whether the association of TRAF2 and TRAF6 
with BAFF-R is through a direct interaction with the BAFF-R 
cytoplasmic  tail  or  indirectly  through TRAF3.  Heteromeric 
TRAF2–TRAF3 complexes have been shown to form in   
B cells (Vallabhapurapu et al., 2008; Zarnegar et al., 2008) so it 
is quite feasible that the association is via this mechanism. How-
ever, the ability of the TRAF3 binding–deficient BAFF-RAVAAA 
mutant to recruit TRAF2 and TRAF6, although diminished 
(Fig. 4 A), suggests that TRAF3 binding may not be required for 
BAFF-R/TRAF2 and TRAF6 associations. The requirements 
within the cytoplasmic tail of BAFF-R for TRAF2 and TRAF6 
associations are currently being analyzed.
The crystal structure of a 24-residue fragment from the 
cytoplasmic domain of BAFF-R bound in complex with 
TRAF3 has been determined (Ni et al., 2004) and the struc-
ture revealed that the 162-PVPAT-166 sequence in BAFF-R 
serves as the recognition motif for binding to TRAF3. Con-
tacts observed in the crystal structure were confirmed by 
protein binding studies, and critical distal residues were also 
identified that mediate TRAF3 recognition, for example, 
T175. The substitution at BAFF-R residue 159 is just three 
residues N-terminal to the PVPAT recognition motif, and this 
residue in BAFF-R may represent an additional contact site for 
TRAF3 binding that has not yet been identified. Inspection of 
the atomic model of the BAFF-R–TRAF3 complex suggests 
that substitution of a tyrosine residue for histidine at this site 
may introduce the potential for formation of a stronger hydro-
gen-binding network, which is consistent with the increased 
binding observed in the present study (K. Ely and S. Mylvaga-
nam, personal communication). Predicted contact residues in 
TRAF3 will be tested in future binding assays.
The  increased  amount  of  TRAFs  recruited  to  BAFF-
RH159Y likely contributes to the increased NF-B activation 
detected in cells expressing the mutant receptor. Our data 
suggest that TRAF6 contributes to activation of the NF-B1 
pathway, although TRAF2 and 3 likely activate NF-B2. 
However, we did not detect any difference in TRAF3 deg-
radation between the BAFF-RH159Y and BAFF-RWT. There-
fore, there may be additional as yet unidentified factors that 
interact with BAFF-R or TRAF2, 3, and/or 6 that mediate 
the enhanced B cell signaling shown by BAFF-RH159Y.
Collectively, our data identify a novel lymphoma-associated 
mutation  in  BAFF-R  and  describe  exciting  new  aspects  of 
BAFF-R signaling that are highly relevant to human B cell biol-
ogy. Building upon these results to obtain a more complete   
understanding of how this signaling is regulated will provide 
valuable information about normal B cell homeostasis and func-
tion and pathogenic BAFF-R contributions to human disease.
MATERIALS AND METHODS
Patient material. The Institutional Review Board at the Mayo Clinic re-
viewed and approved this study. DNA and tumor tissue from NHL patients and 
normal controls was acquired in an ongoing clinic-based case-control study at 
the Mayo Clinic upon providing written informed consent. Details of patient 
specimens are available elsewhere (Cerhan et al., 2007; Novak et al., 2009).
a contributing factor to enhanced NF-B activation in a sub-
set of patients. Although addressing the oncogenic capabili-
ties of BAFF-RHis159-Tyr is beyond the scope of this initial 
study, data presented in this paper do suggest that this muta-
tion contributes to dysregulated signaling through BAFF-R. 
The presence of the mutation may be of particular conse-
quence in individuals who also have high serum BAFF levels, 
as the combined effect of elevated BAFF and the BAFF-
RHis159-Tyr mutation may create a scenario where B cells have 
constitutive  and  dysregulated  signaling  through  BAFF-R. 
The enhanced activation of both NF-B1 and NF-B2 path-
ways detected in cells transfected with BAFF-RHis159-Tyr was 
consistent across cell lines and using two different receptor 
models. The contribution of BAFF-RHis159-Tyr to cell survival 
and proliferation could not be analyzed in the human or 
mouse B cell lines used for our studies as a result of their nat-
urally high proliferative capacity. To address these issues, we 
are generating a transgenic BAFF-RHis159-Tyr mouse to better 
model how this mutation contributes to B cell signaling de-
fects and lymphomagenesis in the intact animal.
Our current understanding of BAFF-R is that it interacts 
with TRAF3 and Act1 adapter proteins in B cells, and the 
mechanistic  role  for  TRAF3  in  BAFF-R–induced  NF-B2   
activation has been the focus of several recent studies. Al-
though others show that TRAF2 and cIAP1/2 are required for   
BAFF-R–induced degradation of TRAF3 and stabilization of 
NIK, the recruitment of TRAF2 or TRAF6 to a BAFF-R–
containing protein complex has not been demonstrated to date 
(Vallabhapurapu et al., 2008; Zarnegar et al., 2008). Our data 
showing that TRAF2 coimmunoprecipitates with the cytoplas-
mic portion of BAFF-R is consistent with previous investiga-
tions showing that direct recruitment of TRAF2 to another 
TNFR superfamily member CD40 is an essential step in CD40-
induced cIAP-mediated TRAF3 degradation (Hostager et al., 
2003; Moore and Bishop, 2005; Vallabhapurapu et al., 2008).
The necessity of TRAF6 for BAFF-R–induced IB phos-
phorylation and degradation clarifies a major question posed by 
the recent generation of the first B cell–specific TRAF6 knock-
out mouse. TRAF6 deficiency reduces mature B cell popula-
tions in the bone marrow and spleen (Kobayashi et al., 2009). 
The authors posit that this deficiency cannot be fully attributed 
to the impaired signaling of TLRs or CD40, implying the in-
volvement of a different receptor. Based on the results presented 
in this paper and the established role of BAFF-R in B cell sur-
vival and homeostasis, we suggest that impaired signaling by 
BAFF-R contributes to the B cell deficiency exhibited by the 
B cell–specific TRAF6-deficient mouse. TRAF6 has been 
shown to be necessary for IL-1–induced phosphorylation of 
IB by acting as an E3 ubiquitin ligase for IKK-/NEMO 
(Lamothe et al., 2007), and TRAF6 may perform a similar role in 
the context of BAFF-R signaling. The recruitment of TRAF6 
by BAFF-R also complements the recent finding that the pro-
tein Act1 acts as an E3 ubiquitin ligase for TRAF6 in the con-
text of IL-17 signaling (Liu et al., 2009). Act1 was shown to be 
recruited to the cytoplasmic portion of BAFF-R after stimula-
tion with BAFF (Qian et al., 2004) and, in this context, could JEM VOL. 207, November 22, 2010 
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NF-B reporter assay. HEK293 cells expressing human WT, H159Y, or 
AVAAA BAFF-R were transiently transfected with 1 ng Renilla and 10 µg 
pNF-B luciferase reporter plasmid or a control reporter plasmid that lacks 
the NF-B DNA sequence. 6 h after transfection, cells were treated with 
200 µg/ml of recombinant human BAFF for 24 h. Luciferase activity was 
measured in cell extracts and normalized against Renilla with the Dual   
Luciferase kit (Promega).
IB phosphorylation assay. A20.2J and A20.2J TRAF6 KO cell lines 
were stimulated with 250 ng/ml of recombinant human BAFF (PeproTech) 
at 37°C. A20.2J and A20.2J TRAF6 KO cells expressing hCD40–BAFF-R 
were stimulated with hCD154. Whole cells were lysed for SDS-PAGE and 
Western blot analyses.
TRAF recruitment to hCD40–BAFF-R. A20.2J B cells expressing 
hCD40–BAFF-R  chimeras  were  immunoprecipitated  using  the  dual 
stimulation-immunoprecipitation  method  described  previously  (Rowland   
et al., 2007). In brief, cells were incubated with 20 µl of protein G Dynabeads 
(Invitrogen) coated with 10 µg G28.5 at 37 or 4°C. Bead-bound cells were 
lysed and cell debris removed by washing to leave only G28.5-associated 
hCD40–BAFF-R and any associating proteins. Levels of hCD40–BAFF-R, 
TRAF2, TRAF3, and TRAF6 were measured by immunoblotting.
IgM  secretion  assay.  CH12.LX  cells  expressing  hCD40–BAFF-RWT  or 
hCD40–BAFF-RHis159-Tyr were incubated with 2 µg/ml anti-mCD40 (1C10), 
anti-hCD40 (G28.5), or isotype control for 72 h to induce secretion of the 
phosphatidyl choline–reactive IgM. IgM-secreting cells were quantified by di-
rect plaque-forming cell assay as previously described (Haxhinasto et al., 2002).
TRAF recruitment to BAFF-R. Mouse A20.2J, human Karpas, or primary 
T cell–depleted mouse splenocytes were stimulated with 500 ng/ml BAFF at 
37°C. Enrichment of the lipid raft fraction was performed by lysing cells in 1% 
Brij58, 150 mM NaCl, 20 mM Tris, 50 mM -glycerophosphate, and EDTA-
free mini-complete protease inhibitor mix (Roche). The Brij58 insoluble frac-
tion was solubilized in 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 20 mM 
Tris, 50 mM  glycerophosphate, and protease inhibitors. This fraction was   
subjected to immunoprecipitation with anti–mouse or anti–human BAFF-R 
(AF1357 and AF1162, respectively; BD). 10–17 × 106 serum-starved HEK293 
cells expressing human WT, H159Y, or AVAAA BAFF-R were incubated with 
200 ng/ml BAFF. Cells were lysed and HA–BAFF-R was immunoprecipitated 
using the ProFound HA tag IP/Co-IP kit (Thermo Fisher Scientific).
Apoptosis assays. A20.2J cells were stimulated with anti–mouse CD40 
(1C10), anti–human CD40 (G28.5) or isotype controls at 10 µg/ml, or anti–
mouse CD95 (BD) or isotype control at 100 ng/ml for 8 h. Subdiploid nu-
clei were detected by PI staining and flow cytometry as previously described 
(Benson et al., 2006). Percentage of rescue was calculated by subtracting the 
number of subdiploid cells after dual anti–mouse CD95 and anti–human 
CD40 stimulation from the number of subdiploid cells after anti–mouse 
CD95 treatment alone. This difference was expressed as a proportion of the 
total number subdiploid cells after anti–mouse CD95 treatment alone.
Statistical  analysis.  All  statistical  comparisons  were  done  using  an   
unpaired Student’s t test. Two-sided p-values <0.05 were considered sta-
tistically significant.
Online supplemental material. Fig. S1 shows schematics of the BAFF-R 
constructs used to transfect HEK293T cells and A20.2J B cells and expres-
sion of the BAFF-R constructs by FACS and immunoblotting. Fig. S2 shows 
cell surface expression of hCD40–BAFF-R chimeras in CH12.LX B cells.   
Fig. S3 shows expression of TRAF1, 2, 3, and 6 in A20.2J B cell transfected with 
hCD40–BAFF-R chimeras. Fig. S4 shows total cellular TRAF6 expression and 
cell surface expression of endogenous mBAFF-R and mCD95 in A20.2J WT 
and A20.2J TRAF6 KO cell lines. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20100857/DC1.
Sequencing of TNFSFR13C and mutation analysis. Genomic germ-
line DNA was isolated from 20 FL patients and 20 normal controls and used 
for the initial sequencing of TNFSFR13C. Purified DNA was amplified by 
PCR using primer pairs that span the TNFSFR13C promoter and each 
exon. PCR fragments were sequenced at the Mayo Clinic DNA Sequencing 
Core Facility and analyzed using Mutation Surveyor software (SoftGenetics). 
Identification of the C519T mutation in DNA isolated from NHL tumor 
biopsies (n = 129) and tissue (PBMC) from normal controls (n = 100) was 
done by restriction fragment length polymorphism (RFLP) analysis and/or 
direct sequencing. For RFLP analysis, a PCR fragment including position 
519 was subjected to restriction enzyme digest with MscI (New England   
Biolabs, Inc.) to confirm the presence or absence of the mutation.
Multiple sequence alignment. BAFF-R amino acid sequences were aligned 
using the ClustalW program. Default parameters were used (Larkin et al., 2007).
Cell lines. The HEK-293 and Karpas-422 cell lines were obtained from the 
American Type Culture Collection and Deutsche Sammlung von Mikro-
organismen und Zellkulturen, respectively. The mouse B cell lines CH12.LX, 
A20.2J, and A20.2J TRAF6 KO have been described previously (Hsing and 
Bishop, 1999; Rowland et al., 2007). Hi5 insect cells infected with WT or 
hCD154-expressing  baculovirus  were  produced  as  described  previously 
(Rowland et al., 2007) and used at a ratio of 1 insect cell to 10 B cells.
Antibodies. Anti-hCD40 (G28.5) and anti–mCD40 (1C10) were produced 
from  a  hybridoma,  and  isotype  control  MOPC21  was  purchased  from 
Sigma-Aldrich. Anti–BAFF-R (ab5965) was purchased from Abcam. Anti–
NF-B2 p52 (05–361) was purchased from Millipore. Anti-TRAF2 (592) 
and anti-TRAF6 (1B1-2) were purchased from MBL International. Anti-
TRAF3 (H122) and anti-YY1 (H-10) were purchased from Santa Cruz Bio-
technology, Inc. Anti–human CD40 was produced by Elmira Biologicals. 
Anti-p52  (4882),  anti–phospho-IB  (2859),  anti-IB  (9242),  anti-
TRAF2 (4724), and anti-TRAF6 (4743) were purchased from Cell Signal-
ing  Technology.  Anti–-actin  (600–501)  was  from  Novus  Biologicals. 
HA-HRP was purchased from Roche. HRP-conjugated secondary anti-
bodies were purchased from Jackson ImmunoResearch Laboratories.
Plasmid construction. BAFF-R H159Y and AVAAA were generated by site-
directed mutagenesis (Invitrogen) and subcloned into pcDNA3.1. The hCD40–
BAFF-R chimeric construct was subcloned into the plasmid pRSV5.neo. The 
His159Tyr transition was introduced to this chimera by overlap extension PCR.
Transfection and stable cell line generation. HA-tagged WT, H159Y, 
or AVAAA BAFF-R constructs were transfected into HEK293 cells with 
Lipofectamine (Invitrogen). Cells were selected in 500 µg/ml G418 (Cell-
gro) and subcloned to generate stable cell lines. A20.2J and CH12.LX B cell 
lines were transfected with pRSV5.neo hCD40–BAFF-R constructs using a 
BTX Electro Square Porator (Harvard Apparatus). Stable clones were main-
tained in 400 µg/ml G418.
Flow cytometry. FITC-conjugated mouse anti–BAFF-R (ab38977) was 
purchased from Abcam. FITC-conjugated anti-hCD40, anti–mBAFF-R, 
and anti-mCD95 and isotype control antibodies were purchased from eBio-
science. Flow cytometry was performed using FACSCalibur (BD) or Guava 
EasyCyte (Millipore) instruments. FlowJo software (Tree Star, Inc.) was used 
for analyses.
p52 and RelB assays. 3 × 106 serum-starved HEK293 cells expressing 
human WT,  H159Y,  or AVAAA  BAFF-R  were  incubated  with  50  or   
200 ng/ml BLyS. Cells were lysed in RIPA buffer and levels of p52 and 
-actin were measured by immunoblotting. For mouse B cells, 3 × 106 
A20.2J  cells  were  incubated  with  10  µg/ml  of  agonistic  anti–human 
CD40 antibody (G28.5). Nuclear extracts were prepared as previously 
described (Rowland et al., 2007) and levels of p52, RelB, and YY1 were 
measured by immunoblotting.2578 BAFF-R mutation in non-Hodgkin lymphoma | Hildebrand et al.
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